Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
企業コードGRFS
会社名Grifols SA
上場日May 17, 2006
最高経営責任者「CEO」Abia (Jose Ignacio)
従業員数23833
証券種類Depository Receipt
決算期末May 17
本社所在地Parque Empresarial Can Sant Joan
都市SANT CUGAT DEL VALLES
証券取引所NASDAQ OMX - NASDAQ BASIC
国Spain
郵便番号08174
電話番号34935710000
ウェブサイトhttps://www.grifols.com/
企業コードGRFS
上場日May 17, 2006
最高経営責任者「CEO」Abia (Jose Ignacio)
過去5年間の配当金総支払額は
436.88M
米ドルである。
GRFS.NB Final Cash Dividend of gross USD 0.175789 paid on Aug 20, 2025 going ex on Aug 12, 2025
GRFS.NB Interim Cash Dividend of gross USD 0.456586 paid on Jun 14, 2021 going ex on Jun 03, 2021
GRFS.NB Interim Cash Dividend of gross USD 0.201439 paid on Nov 09, 2020 going ex on Oct 30, 2020